Company intelligence / Profile preview
Immuneel Therapeutics
Bengaluru, Karnataka, Indiaimmuneel.com ↗
- Ownership
- Private
- Employees
- ~47
- Development stage
- Phase 2
01
Overview
Immuneel's flagship product Qartemi (varnimcabtagene autoleucel - IMN-003A) has shown potential to provide lasting remission of relapsed and refractory NHL, even when conventional therapies including chemotherapy prove ineffective. Clinical trials in India and Spain show safety and efficacy similar to FDA-approved CAR-T therapies, at one-tenth the cost of similar products in the US[6].
- Therapeutic areas
- OncologyHematology
- Modalities
- Cell and gene therapiesCAR-T cell therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Hospital Clinic de Barcelona (HCB)Institut d'Investigacions Biomèdiques August Pi i Sunyer
Beyond the preview
Go deeper on Immuneel Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immuneel Therapeutics.